Ribosome biogenesis is a therapeutic vulnerability in pediatric neuroblastoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Neuroblastoma is a complex pediatric cancer with prognosis dependent on age, stage, and genetic factors like MYCN.
• MYC oncogene activity relies on hyperactivated ribosome biogenesis, a potential vulnerability in cancer cells.
• Current treatments for neuroblastoma consider age, histology, genomic profile, and MYCN status.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting ribosome biogenesis in neuroblastoma.
• To identify novel therapeutic targets within the ribosome biogenesis pathway.
• To evaluate the role of Fibrillarin (FBL) as a prognostic marker and therapeutic target in neuroblastoma.

Main Methods:

• Utilized IMR-32 and patient-derived neuroblastoma cell lines with varying MYCN status.
• Administered RNA polymerase I inhibitors (CX-5461, BMH-21) to assess effects on cell proliferation and apoptosis.
• Analyzed ribosome biogenesis factor expression using public datasets and in-house cohort RT-qPCR data.
• Performed Fibrillarin (FBL) knockdown experiments to evaluate its impact on neuroblastoma cell proliferation.

Main Results:

• RNA polymerase I inhibition suppressed neuroblastoma cell proliferation at nanomolar concentrations, inducing ribosomal stress, apoptosis, and p21 pathway activation.
• Fibrillarin (FBL) was identified as a marker of poor prognosis in neuroblastoma.
• FBL knockdown significantly reduced neuroblastoma cell proliferation, confirming its relevance as a therapeutic target.

Conclusions:

• Ribosome biogenesis inhibition is a promising therapeutic strategy for neuroblastoma.
• Fibrillarin (FBL) represents a novel therapeutic target in neuroblastoma treatment.
• Targeting rRNA maturation factors offers expanded therapeutic avenues for neuroblastoma.